Jay Schachner, MD
Basic profileThe University of Texas MD Anderson Cancer Center
Jay Schachner is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 10 publications with 527 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
690 N 14th St
3rd Floor
Beaumont, TX 777021449
Telephone
409-899-7180Registry record last updated 11 Apr 2017.
Industry payments
48 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202514 payments
- AstraZeneca Pharmaceuticals LPProgram year20257 payments
- Novartis Pharmaceuticals CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
69.9%Parenteral Iron Replacement53.4%Iron sucrose100%Part B, office-administered≥35 patientsErythropoiesis-stimulating Agent16.4%Darbepoetin alfa100%Part B, office-administered≥17 patients+ 1 more class in this area
Metabolism & gastrointestinal
22.9%Other antiemetics18.6%Fosaprepitant100%Part B, office-administered≥11 patientsSerotonin-3 Receptor Antagonist2.7%Palonosetron hcl52%Granisetron hydrochloride42%Ondansetron Hcl6%Part D + Part B≥16 patients+ 5 more classes in this area
Sensory organs
4%Corticosteroid4%Dexamethasone sodium phosphate100%Part B, office-administered≥46 patientsFluoroquinolone Antibacterial0%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Use of Granulocyte-Macrophage Colony-Stimulating Factor Prior to Chemotherapy of Newly Diagnosed AML
Hämatologie und Bluttransfusion
1992 - Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
Journal of Clinical Oncology
1991
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”